Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos compuestos para tratar la leishmaniosis

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20170206001
Publicado:
09/02/2017
Caducidad:
09/02/2018
Resumen:
Un grupo de investigación de una universidad española ha desarrollado una nueva clase de compuestos para el tratamiento de la leishmaniosis con un nuevo modo de acción, baja toxicidad y alta eficacia frente al parásito. La vehiculización de estos compuestos se realiza con nanopartículas farmacéuticamente aceptables, como nanopartículas de oro. El grupo de investigación busca empresas con el fin de comercializar los compuestos veterinarios o continuar con el desarrollo de estos compuestos para uso en humanos. El objetivo es establecer acuerdos de licencia.

Details

Tittle:
New compounds for treating Leishmaniasis
Summary:
A research group from a major Spanish university have developed a new class of compounds for the treatment of Leishmaniasis with a new mode of action, low toxicity and high efficacy against the parasite. The research group is looking for companies to market veterinary compounds, or develop further for potential use in man, under a license agreement.
Description:
Leishmaniasis (also spelled leishmaniosis) is a disease caused by parasites which can affect humans and animals and is spread by the bite of certain types of sandflies. It is one of the most important tropical diseases, but it is not limited to these regions, being present in other warm places such as Southern Europe, where it is considered an endemic disease amongst dogs and often leads to the death of the animals if not treated.

The drugs that are currently used for treating leishmaniasis show different problems:
- High toxicity
- Severe adverse effects
- Appearance of resistances
- High cost

Scientists from a mayor Spanish university have developed a new class of compounds for the treatment this disease. The specific treatment reduces signs and symptoms of canine leishmaniasis and allows the dog to coexist with the parasite, which rarely is completely eliminated.

The new compounds are effective against parasites of leishmaniasis showing a low toxicity even at high doses.The vehiculization of these compounds is made by using pharmaceutically aceptable nanoparticles, such as gold nanoparticles.

The group is looking for a company in order to reach a license agreement.
Advantages and Innovations:
- high efficacy towards parasites of leishmaniasis

- low toxicity even at high doses

- can also potentially be administered orally

Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent application for this invention was filed in July 2016

Partner sought

Type and Role of Partner Sought:
- Type of partner sought:
Industry

- Specific area of activity of the partner:
Pharmaceuticals / Veterinary medicine

Task to be performed:
To market the compound for the veterinary sector and to keep on developing and improving the compound for a potential use on humans.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos